Research graph
References from Case Report: Pembrolizumab–induced myasthenia gravis with isolated anti-titin antibody positivity after thymectomy for thymoma. Local targets link to admitted publications; unresolved targets remain external evidence.
Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms
10.1016/j.jaut.2013.12.011 · 2014 · External reference
Severe myositis, myocarditis, and myasthenia gravis with elevated anti‐striated muscle antibody following single dose of ipilimumab‐nivolumab therapy in a patient with metastatic melanoma
10.1155/2019/2539493 · 2019 · External reference
Immune checkpoint inhibitor-induced polymyositis and myasthenia gravis with fatal outcome
10.1159/000510740 · 2021 · External reference
The terrible triad of checkpoint inhibition: a case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma
10.1155/2020/5126717 · 2020 · External reference
Immune checkpoint inhibitor-induced Myasthenia gravis
10.3389/fneur.2020.00634 · 2020 · External reference
Anti-titin antibody, one of the antistriational autoantibodies was found in a case of seronegative myasthenia gravis associated with anti-PD-1 therapy
10.1016/j.jns.2017.08.3224 · 2017 · External reference
Myasthenia gravis appearing after thymectomy for thymoma
10.1016/j.ejcts.2005.03.039 · 2005 · External reference
Immune checkpoint inhibitor-induced myasthenia gravis in a patient with advanced NSCLC and remote history of thymoma
10.1016/j.cllc.2019.04.007 · 2019 · External reference
Incidence of thymoma in myasthenia gravis: a systematic review
10.3988/jcn.2012.8.3.161 · 2012 · External reference
Muscle autoantibodies in myasthenia gravis: beyond diagnosis?
10.1586/eci.12.34 · 2012 · External reference
Pembrolizumab-induced ocular myasthenia gravis with anti-titin antibody and necrotizing myopathy
10.2169/internalmedicine.1956-18 · 2019 · External reference
Nivolumab-induced myositis and myocarditis with positive anti-titin antibody and anti-voltage-gated potassium channel Kv1. 4 antibody
10.2169/internalmedicine.8772-21 · 2022 · External reference
Myastenic syndrome diagnosed after treatment of small cell lung cancer with Atezolizumab (PDL-1 inhibitor)
10.14744/ejma.2023.47966 · 2023 · External reference
Myasthenia gravis and concurrent myositis following PD-L1 checkpoint inhibitor for non-small cell lung cancer
10.1136/bmjno-2019-000028 · 2020 · External reference
Immune checkpoint blockade in cancer therapy
10.1200/jco.2014.59.4358 · 2015 · External reference
Immune-related adverse events associated with immune checkpoint blockade
10.1056/nejmra1703481 · 2018 · External reference
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature
10.1186/s40425-019-0774-y · 2019 · External reference
A case of myositis with dropped head syndrome and anti-titin antibody positivity induced by pembrolizumab
10.1080/03009742.2020.1760346 · 2020 · External reference
De novo myasthenia gravis induced by atezolizumab in a patient with urothelial carcinoma
10.7759/cureus.5002 · 2019 · External reference
Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients
10.1001/archneur.58.6.885 · 2001 · External reference
Immune-related adverse events of immune checkpoint inhibitors: a review
10.3389/fimmu.2023.1167975 · 2023 · External reference
